Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Date:6/4/2009

atements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The Company is evaluating the complete response letter from the FDA and there can be no assurance that the Company will either amend its supplemental BLA or conduct future clinical studies with Cinryze as a treatment for acute attacks of hereditary angioedema. In the event the Company does conduct additional clinical studies, there can be no assurance that such studies will demonstrate that Cinryze successfully treats acute hereditary angioedema attacks or that the FDA will ever approve Cinryze for the acute treatment of hereditary angioedema. In addition, there can be no assurance that the FDA will not approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2009, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two June Healthcare Conferences
2. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
3. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
4. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
5. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
9. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
10. ViroPharma to Present at Three October Healthcare Conferences
11. ViroPharma to Present at Three September Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)...   MSC , a healthcare performance improvement company ... appointment of Mary Beth Loesch to President ... experience preparing companies for rapid growth and market expansion, ... of Corporate Development and Healthcare. In that role, she ... well as corporate strategy and marketing. Previously, Loesch served ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... SAN DIEGO, Oct. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the 28th Annual Scientific Meeting of ... the San Diego Convention Center, October 8-12, 2010.Sunday, October ...
... Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that ... Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT ... Live webcasts from this conference will be available through the ... http://ir.oncogenex.com . Webcast replays will be available approximately two hours ...
... RAMAT GAN, Israel, October 4, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 3EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 4EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 5EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 6EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 7
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
(Date:8/27/2014)... N.C. -- Duke University researchers have identified a gene ... called OSCA1, encodes a protein in the cell membrane ... adjusts the plant,s water conservation machinery accordingly. , ... associate professor of biology at Duke. , The ... Nature , could make it easier to feed the ...
(Date:8/27/2014)... requires nerve cells to rearrange existing patterns of activity ... patterns, a study of monkeys has found. The scientists ... electrical activity of brain cell networks. The study was ... "We looked into the brain and may have seen ... said Aaron Batista, Ph.D., an assistant professor at the ...
Breaking Biology News(10 mins):Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Water 'thermostat' could help engineer drought-resistant crops 2Scientists plug into a learning brain 2Scientists plug into a learning brain 3
... abnormality that appears to prevent some men from conceiving ... contraceptive, according to University of Iowa researchers reporting their ... American Journal of Human Genetics . Although ... and have proven very effective for family planning, no ...
... A major effort from within the Aspergillus community ... supplement by the Elsevier journal Fungal Genetics ... provides extensive studies based on the genome analysis ... nidulans. The publication was enabled by Eurofungbase, a ...
... student Alistair Boettiger has amassed a beautiful collection of ... them in his computer. He and George Oster, ... mathematical neuroscientist Bard Ermentrout, have written a computer program ... principles developed to explain how the brain works and ...
Cached Biology News:Gene discovery could lead to male contraceptive 2Mollusks taste memories to build shells 2Mollusks taste memories to build shells 3Mollusks taste memories to build shells 4
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: